MiNK Therapeutics (INKT) Net Cash Flow (2020 - 2026)
MiNK Therapeutics (INKT) posted Net Cash Flow of -$3.8 million for Q1 2026, down 326.59% sequentially from -$898623.0 in Q4 2025, and down 186.01% YoY from $4.5 million in Q1 2025.
MiNK Therapeutics (INKT) Net Cash Flow (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$3.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 186.01% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 348.13% YoY) and the FY2025 annual result came in at $8.8 million, up 595.66% from the prior year.
- Net Cash Flow eased to -$3.8 million in Q1 2026 per INKT's latest filing, from -$898623.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $12.6 million in Q3 2025 and troughed at -$5.7 million in Q3 2022.
- A 5-year average of -$1.7 million and a median of -$3.0 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow tumbled 673.28% in 2022, then soared 521.82% in 2025.
- Over 5 years, Net Cash Flow stood at -$4.6 million in 2022, then soared by 33.4% to -$3.0 million in 2023, then soared by 43.09% to -$1.7 million in 2024, then surged by 47.99% to -$898623.0 in 2025, then sank by 326.59% to -$3.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$3.8 million, -$898623.0, and $12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | MiNK Therapeutics | 57.77 Mn | 57.77 Mn | - | -716,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -716,658.00 |
| Jun 30, 2026 | -716,658.00 |
| Mar 31, 2026 | -3.83 Mn |
| Mar 31, 2026 | -3.83 Mn |
| Dec 31, 2025 | -898,623.00 |
| Dec 31, 2025 | -898,623.00 |
| Sep 30, 2025 | 12.60 Mn |
| Sep 30, 2025 | 12.60 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Jun 30, 2025 | -1.57 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Sep 30, 2024 | -2.99 Mn |
| Sep 30, 2024 | -2.99 Mn |
| Jun 30, 2024 | 3.52 Mn |
| Jun 30, 2024 | 3.52 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Mar 31, 2024 | 2.46 Mn |